TROP2 Targeted Therapy: Module

CME

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 22, 2024

Expiration: February 21, 2025

Komal Jhaveri
Komal Jhaveri, MD, FACP

Activity

Progress
1 2
Course Completed

Rationale for Targeting TROP-2 in Breast Cancer

Trophoblast cell-surface antigen-2 (TROP-2), also known as tumor-associated calcium signal transducer 2, plays an important role in cell proliferation, self-renewal, and transformation. TROP-2 is a pan-epithelial cancer antigen that is highly expressed on the membrane surface of multiple cancer types but expressed at very low levels on the surface of many normal epithelial cells, making it an attractive target for the treatment of cancer.1 Although TROP-2 is overexpressed across all breast cancer subtypes, its level is most elevated in triple‑negative breast cancer (TNBC). In TNBC in particular, elevated expression of TROP-2 levels has been linked to disease aggression and chemotherapy resistance. As a result, TROP-2‒directed therapies are increasingly being investigated in the relapsed/refractory breast cancer setting, and the TROP-2‒targeted ADC sacituzumab govitecan now has been incorporated into the therapeutic algorithm for patients with advanced TNBC, for whom limited effective treatment options are available.2 In fact, sacituzumab govitecan also is indicated for patients with advanced HR-positive/HER2-negative breast cancer who have received endocrine-based therapy and ≥2 additional systemic therapies in the metastatic setting.